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Abstract
 
A number of in vitro studies have suggested that costimulatory molecules B7-1 and B7-2 and
their receptor CD28 can promote clonal deletion, and limited in vivo studies have indicated
that CD28 is involved in the clonal deletion of some T cells. However, the significance of B7-
mediated clonal deletion in preventing autoimmune diseases has not been studied systemati-
cally. Here we report that the perinatal blockade of B7-1 and B7-2 substantially inhibits the
clonal deletion of T cells in the thymus and leads to an accumulation of T cells capable of in-
ducing fatal multiorgan inflammation. These results reveal a critical role for costimulatory mol-
ecules B7-1 and B7-2 in deleting pathogenic autoreactive T cells in the thymus. The critical
role of B7-1 and B7-2 in T cell clonal deletion may explain, at least in part, the paradoxical in-
crease of autoimmune disease in mice deficient for this family of costimulatory molecules, such
as cytotoxic T lymphocyte associated molecule 4, CD28, and B7-2. The strong pathogenicity
of the self-reactive T cells supports a central hypothesis in immunology, which is that clonal
deletion plays an important role in preventing autoimmune diseases.
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Introduction
 
Mice with a targeted mutation in one of the B7 receptors,
CD28 or cytotoxic T lymphocyte–associated molecule 4
 
(CTLA-4)
 
*
 
 (1, 2), have either a rapid onset of fatal au-
toimmune lymphoproliferative disease (3, 4), or accelerated
autoimmune diabetes in a predisposed nonobese diabetic
(NOD) background (5). More recently, autoimmune neu-
ropathy was reported in NOD mice with a targeted muta-
tion of B7-2 (6). The phenotypes of the CTLA-4–deficient
mice have been attributed to CTLA-4’s negative regulatory
function by many (3, 4), although not by all investigators
(7, 8). The enhanced autoimmunity in mice with muta-
tions of CD28 or B7-2, the prototypic costimulatory mole-
cules, suggests that the autoimmune phenotype caused by
mutations in these genes cannot necessarily be attributed to
functions of these molecules in T cell activation, as their
blockade in adult mice clearly reduces the incidence and
severity of diabetes (9). A largely unexplored issue is
whether the blockade of costimulatory molecules during T
cell development may increase the number and spectrum of
potential autoreactive T cells, and if so, whether this effect
contributes, at least in part, to the paradoxical autoimmune
phenotypes of these mice.
Since the identification of B7-1 and B7-2 as the proto-
typic costimulatory molecules in T cell activation, there has
been considerable interest in their potential contribution in
T cell development. Several lines of evidence indicate that
costimulatory molecules can contribute to the negative se-
lection of T cells. First, B7-1 and B7-2 are expressed at sig-
nificant levels in the thymic dendritic cells (10) and medulla
epithelial cells (11, 12). Given the accepted roles for these
cells in the clonal deletion of T cells (13, 14), it is reason-
able to test whether B7-1 and B7-2 on them contributes to
the efficacy of T cell clonal deletion. Second, agonistic
anti-CD28 mAb enhanced the death of immature T cells
induced by ligation of the TCR–CD3 complex (15).
Third, the blockade of B7-1 and B7-2 in thymic organ cul-
ture reduced the efficacy of clonal deletion in thymic organ
culture (16). Fourth, clonal deletion induced by low doses
of antigenic peptide or bacteria superantigen was reduced
 
in CD28
 
 
 
/
 
 
 
 mice (17). Fifth, a recent report showed that
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clonal deletion induced by endogenous viral superantigen
was significantly affected by the targeted mutation of
CD28
 
 
 
/
 
 
 
 (18). Collectively, these studies demonstrated
that B7-1 and B7-2 can promote the clonal deletion of au-
toreactive T cells, although the biological significance of
B7-mediated T cell clonal deletion has not been systemati-
cally analyzed.
Although T cell development proceeds throughout
much of one’s life span, the perinatal period is the most
critical in establishing the T cell repertoire. Here we tested
the effect of a transient blockade of both B7-1 and B7-2
during the perinatal period on the accumulation of patho-
genic self-reactive T cells. Using transgenic mice that ex-
press both antigen and TCR, we report that perinatal treat-
ment with anti–B7-1 and anti–B7-2 prevents T cell clonal
deletion in vivo. In addition, in mice with polyclonal T
cell repertoire, we show that clonal deletion by viral super-
antigen (VSAg) is substantially reduced by perinatal anti-B7
treatment. More importantly, the T cells, rescued by the
anti-B7 mAbs, cause severe autoimmune destruction in
syngeneic recipients upon adoptive transfer. These results
reveal a critical role of B7-1 and B7-2 in tolerizing patho-
genic autoreactive T cells and suggest that this function
may contribute, at least in part, to the paradoxical increase
in autoimmune disease in mice with targeted mutations of
costimulatory molecules.
 
Materials and Methods
 
Experimental Animals.
 
Recombinase activating gene 1 (RAG-
1)–deficient and wild-type C57BL/6j mice were purchased from
The Jackson ImmunoResearch Laboratories and maintained in
the University Laboratory Animal Research Facility at Ohio State
University (Columbus, OH) under specific pathogen-free condi-
tions. Transgenic mice expressing tumor antigen P1A/TCR spe-
cific for tumor antigen P1A have been described elsewhere (19).
Mice at day 16 of pregnancy, and those 2-, 3-, or 6-wk-old, were
used for the current study. Nu
 
 
 
/nu
 
 
 
 C57BL/6j littermates were
purchased from Taconic and used as the recipients of the adoptive
transfer at 14-d-old.
 
Perinatal Blockade of B7-1 and B7-2 Using Specific mAbs.
 
On
days 16 and 19 of pregnancy, the female mice were injected in-
traperitoneally with 100 
 
 
 
g of mAb per mouse of anti–B7-1
(3A12, hamster IgG) and anti–B7-2 (GL-1, rat IgG2a) mAbs.
The newborn mice were injected intraperitoneally with the same
mAbs at a reduced dose (25 
 
 
 
l of mAb per mouse) on days 0, 3,
6, and 9. Control mice were injected with an equivalent amount
of normal hamster IgG (Rockland Inc.) and rat IgG (Sigma-
Aldrich). The spleen cells and thymocytes were either analyzed
by flow cytometry or used for adoptive transfer.
 
Flow Cytometry.
 
Both cell surface markers and intracellular cy-
tokine production were analyzed by flow cytometry. Cell surface
markers CD25, CD44, CD69, and CD62L, and V
 
 
 
3, V
 
 
 
5, V
 
 
 
8,
V
 
 
 
11, and V
 
 
 
12 were analyzed with conjugated mAbs purchased
from BD PharMingen. For intracellular cytokine production,
spleen cells were stimulated with 40 ng/ml of PMA and 10 
 
 
 
M of
ionomycin (both from Sigma-Aldrich) for 6–9 h. 5 
 
 
 
M of mo-
nensin (Sigma-Aldrich) was added 1 h after culture. The intracellu-
lar IL-2, IL-4, IL-10, or IFN-
 
 
 
 were analyzed using a kit from BD
PharMingen according to the manufacturer’s instructions.
 
Adoptive Transfer.
 
The given numbers of thymocytes from
mice that received either anti-B7s or control IgG during the peri-
natal period were incubated with anti-CD8 mAbs (clone 2.43, rat
IgG2b, 5 
 
 
 
g/ml) at 4
 
 
 
C for 30 min. After the removal of un-
bound mAbs, the antibody-coated thymocytes were removed by
anti-Ig–coated magnetic beads as instructed by the manufacturer
(Biosource International). The CD4 T cell–enriched thymocytes
were injected intraperitoneally into syngeneic RAG-1
 
 
 
/
 
 
 
 mice.
In other experiments, spleen T cells were purified by the deple-
tion of MHC class II
 
 
 
 and FcR
 
 
 
 cells using mAbs to I-A (M5/
114, rat IgG2b) and to Fc
 
 
 
 receptors (CD16/CD32; 2.4G2, rat
IgG2b) and adoptively transferred into either RAG-1
 
 
 
/
 
 
 
 or nu
 
 
 
/
nu
 
 
 
 C57BL/6j mice.
 
Histological Analysis.
 
Mouse organs were fixed with 10%
buffered formalin and were paraffin embedded. Tissue sections
were stained with hematoxylin and eosin (H&E), and examined
under a microscope. In some experiments, frozen sections were
prepared and stained with 2 
 
 
 
g/ml of antibodies specific for dif-
ferent subsets of leukocytes, Mac-1 (M1/70, rat IgG2b), CD4
(GK1.5, rat IgG2b), CD8, or variable regions of the TCR
 
 
 
chain (V
 
 
 
3 and V
 
 
 
11). Pathological score (0–4) is based on the
average numbers/size of inflammatory lesions per organ section:
0, no infiltrates; 1, 1 to 2 lesions; 2, 2 to 3 lesions; 3, 4 to 5 le-
sions; and 4, 
 
 
 
6 lesions or inflammation covering more than
50% of the organ section.
 
Acute Syngeneic GVHD.
 
Spleens or CD4 T cell–enriched
thymocytes harvested from mice perinatally treated with anti-B7
were incubated with a mixture of FITC–anti-V
 
 
 
3, -V
 
 
 
5, -V
 
 
 
11,
and -V
 
 
 
12 mAbs for 15 min at 4
 
 
 
C. After removing the un-
bound mAbs, anti-FITC beads were added. The cells bound to
the MACS
 
®
 
 beads were enriched using the MACS
 
®
 
 system™
(Miltenyi Biotec), according to the manufacturer’s instructions.
After purification, analysis indicated that among enriched spleen
cells, 80% of the CD4 T cells and 90% of the CD8 cells had ex-
pressed the V
 
 
 
 of interest. The purified cells were injected intra-
venously with 10
 
6
 
 spleen T cells per mouse into the lethally irra-
diated mice that had each received 10
 
7
 
 bone marrow cells from
syngeneic mice. Both V
 
 
 
3-, V
 
 
 
5-, V
 
 
 
11-, V
 
 
 
12-expressing (3 
 
 
 
10
 
6
 
 per mouse, enriched) and nonexpressing (3 
 
 
 
 10
 
7
 
 per mouse,
depleted) thymocytes were used for adoptive transfer. About 50%
of the enriched thymocytes expressed the V
 
 
 
 of interest, whereas
the depleted population contained no detectable V
 
 
 
3-, V
 
 
 
5-,
V
 
 
 
11-, and V
 
 
 
12-expressing cells. The thymocytes were in-
jected intravenously in conjunction with 10
 
7
 
 bone marrow cell.
3–4 wk after the adoptive transfer, the recipient mice were killed
and analyzed for the TCR representation, pathology, and tissue
infiltration by V
 
 
 
3- and V
 
 
 
11-expressing T cells.
 
Results
 
Perinatal Blockade of B7-1 and B7-2 Inhibited T Cell Clonal
Deletion of Antigen-specific T Cells In Vivo.
 
We have re-
cently produced a transgenic mouse line that overexpresses
tumor antigen P1A in the thymus and in the spleen, and
another transgenic line that expresses H-2L
 
d
 
–restricted,
P1A-specific TCR (P1CTL) (19). We reported that thy-
mic expression of P1A led to the clonal deletion of P1A-
specific T cells in the P1CTL
 
 
 
/P1A
 
 
 
 mice (19). To test
the effect of B7 blockade in T cell development, we bred
P1A transgenic mice with the TCR transgenic mice and
injected anti-B7 or control antibodies from E16 to day 10
after birth. The effects of anti-B7 mAbs on the littermates 
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that expressed either P1CTL TCR alone or both TCR and
the P1A in the thymus were analyzed by flow cytometry
on day 15 after birth. As shown in Fig. 1 a, perinatal treat-
ment with anti-B7 mAbs substantially increased the num-
ber of T cells in the double transgenic mice. Within the
control IgG-treated group, expression of P1A led to the
clonal deletion of P1CTL, as indicated by a reduction in
the total number of thymocytes and a specific reduction of
the number of CD4
 
 
 
CD8
 
 
 
 thymocytes (Fig. 1 b). Both ef-
fects were reversed by perinatal treatment with anti-B7
mAbs. These results demonstrated that anti-B7 mAbs pre-
vented the clonal deletion of the P1A-specific T cells.
Interestingly, the anti-B7 treatments also increased the
number of T cells and altered the ratio of CD8
 
 
 
CD4
 
 
 
/
CD4
 
 
 
CD8
 
 
 
 thymocytes in the P1CTL
 
 
 
/P1A
 
 
 
 mice (Fig.
1 b, left). Because P1A is an unmutated tumor antigen with
limited expression in normal mice (19), including thymic
medulla epithelial cells (20) that can mediate negative selec-
tion (11, 13), it is possible that anti-B7 treatment may de-
crease the clonal deletion induced by endogenous P1A an-
tigen. A partial deletion of CD8
 
 
 
CD4
 
 
 
 T cells can lead to
a relative increase in the proportion of CD4
 
 
 
CD8
 
 
 
 T cells
in the thymus, as observed in the control group. It should
also be noted that in this (Fig. 1 b, which depicts the
TCR
 
 
 
 cells only) and other TCR-transgenic models (21,
22), clonal deletion caused a substantial increase in the per-
centage of CD4
 
 
 
CD8
 
 
 
TCR
 
 
 
 cells. The specific decrease
in the proportion of the CD4
 
 
 
CD8
 
 
 
 T cells (Fig. 1 b) by
anti-B7 is consistent with the notion that anti-B7 blocked
the clonal deletion of P1A-specific T cells. Thus, B7-1 and
B7-2 are critical for the clonal deletion of P1A-specific au-
toreactive T cells in the thymus.
It has been demonstrated that strong peripheral immune
response can lead to antigen-independent deletion of
thymocytes, particularly the immature CD4
 
 
 
CD8
 
 
 
 thy-
mocytes (23). An interesting issue is whether anti-B7 in-
creases the number of thymocytes by preventing the
 
antigen-dependent clonal deletion or by inhibiting the pe-
ripheral T cell activation. To address this issue, we took ad-
vantage of the fact that allelic exclusion at TCR V
 
 
 
 locus is
incomplete, and we analyzed the composition of V
 
 
 
8
 
 
 
 thy-
mocytes that utilize endogenous V
 
 
 
 genes and are therefore
not specific for P1A. As shown in Fig. 1 c, the subset distri-
bution of the V
 
 
 
8
 
 
 
 cells was normal in the double trans-
genic mice and was not affected by anti-B7 treatment.
Thus, the effect of anti-B7 is primarily to inhibit the anti-
gen-dependent T cell clonal deletion in the thymus.
To test whether the autoreactive T cells migrated to the
periphery, we analyzed the number and the phenotypes of
the transgenic T cells in the spleens on day 15 after birth.
As shown in Fig. 2, although anti-B7 treatment did not sig-
nificantly alter the number of transgenic T cells in the P1A
and P1CTL of double transgenic mice (
 
P
 
   
 
0.16), it sub-
stantially increased the percentage and numbers (Fig. 2) of
CD8
 
 
 
V
 
 
 
8
 
 
 
 T cells (
 
P
 
 
 
  
 
0.02). In P1CTL single transgenic
mice, anti-B7 somewhat increased the number of trans-
genic T cells. The biological significance of this occurrence
is not yet clear. Because the T cells constituted a small frac-
tion of the spleen cells, the total number of spleen cells was
not significantly affected by anti–B7-1 and anti–B7-2. As
shown in Fig. 2, the P1A transgene caused a drastic reduc-
tion in the percentage of CD8
 
 
 
V
 
 
 
8
 
 
 
 T cells in the spleen.
This effect was substantially blocked by the anti-B7 treat-
ment. In the mice that received anti-B7 treatment, the ac-
cumulated transgenic T cells exhibited phenotypes of acti-
vated T cells, as they were larger in size and higher in the
level of CD44 (Fig. 2, bottom). These results demonstrated
that the transgenic T cells in the spleen of anti–B7-treated
mice were stimulated by antigen in vivo. Because this was
not observed in anti–B7-treated mice that expressed trans-
genic TCR, but not the P1A antigen, the high number of
CD44
 
high
 
-transgenic T cells was induced primarily by the
transgenic P1A antigen. Thus, the T cells rescued by anti-
B7 treatment may have responded to the P1A antigen. In
Figure 1. Anti-B7 blockade in
the perinatal period (from E16 to
day 10 after birth) significantly re-
duced the efficacy of T cell clonal
deletion, analyzed on day 15 after
birth. (a) Anti-B7 mAb increased the
total number of thymocytes in trans-
genic mice expressing both the T
cell receptor and its specific antigen.
Data shown are summarized from
three independent experiments.
Each point represents one double
transgenic mouse. (b) Thymocyte
composition in TCR single trans-
genic (P1CTL /P1A ) or TCR
P1A double transgenic (P1ACTL /
P1A ) mice. Transgenic thy-
mocytes were analyzed by three-
color flow cytometry using anti-
V 8, anti-CD4, and anti-CD8
mAbs. The number of thymocytes is given at the bottom of each panel, and the percentage of the V 8  cells is provided in the parentheses. Data shown
are profiles of gated V 8  T cells and are representative of three independent experiments. (c) The subset distribution of gated V 8  T cells from either
anti-B7 or control Ig-treated double transgenic mice. The percentage of the gated population is presented at the bottom of each panel.962 A Critical Role for Costimulation in Clonal Deletion of Autopathogenic T Cells
contrast, the T cells in the spleens of control IgG-treated
mice were smaller in size and were comprised of substan-
tially less CD44high subset, which suggested that these T
cells were hyporesponsive to the endogenous P1A antigen.
Perinatal Treatment with Anti-B7 Prevents the Effective
Clonal Deletion of T Cells Specific for the Viral Superantigens.
The viral superantigens (VSAg) are the most effective in-
ducers of T cell clonal deletion. Although the deletion of T
cells for conventional antigens is generally investigated in
TCR-transgenic mice due to a low frequency of T cells
specific for a given antigen in normal mice, VSAg-reactive
T cells can be investigated with wild-type mice. Moreover,
the clonal deletion takes place at a late stage in the medulla
(24). Here we used wild-type BALB/c mice to investigate
the deletion of T cells specific for endogenous viral super-
antigens. BALB/c mice have integrations of mouse mam-
mary tumor provirus types 6, 8, and 9. As a result, the ma-
jority of T cells expressing V 3, V 5, V 11, and V 12
have been deleted (25). To test the role for B7-1 and B7-2
in the clonal deletion of T cells reactive to viral superanti-
gens, we treated BALB/c mice during the perinatal period
with either control IgG or anti-B7 mAbs. 4 wk after birth,
the thymus, spleen, and lymph nodes were harvested, and
the clonal deletion of T cells was analyzed using a cocktail
of anti-CD4, anti-CD8, and anti-V  mAbs. Profiles of the
gated single-positive thymocytes from a representative thy-
mus from control IgG- and anti–B7-treated groups are pre-
sented in Fig. 3 a, whereas the summary data of mature
CD4 or CD8 T cells in the thymus, spleen, and lymph
nodes are presented in Fig. 3 b.
Among the CD4 CD8  thymocytes, anti-B7 treatment
increased V 5 , V 11 , and V 12  T cells by three- to
fourfold. An almost twofold increase of V 3  CD4 T cells
was also found in anti–B7-treated mice. Reflecting the in-
crease in the VSAg-reactive CD4 T cells, a significant re-
duction in the VSAg-nonreactive V 8 CD4 T cells was
observed. Among the CD4 CD8  thymocytes, the dele-
tion of V 3  T cells was not affected by anti-B7 treatment,
whereas the effect of anti-B7 on the deletion of V 5  cells
was insignificant because the deletion varied widely among
individual untreated mice. In contrast, anti-B7 increased
the proportion of V 11  CD8 T cells by almost twofold,
and that of V 12  cells by threefold. These results clearly
demonstrate that B7-1 and B7-2 played a major role in the
clonal deletion of a large array of VSAg-specific T cells in
the thymus.
The effects of anti-B7 treatment on the number of
VSAg-specific T cells in the spleen and lymph node gener-
ally recapitulated those in the thymus (Fig. 3 b). Two
points are worth noting. First, in contrast to the thymus,
the effect of anti-B7 on the V 5  CD8 T cells in the pe-
riphery was highly significant. Thus, anti-B7 significantly
inhibits clonal deletion of all subsets of VSAg-reactive CD4
cells, and that of all but V 3 CD8 T cells. Second, regard-
less of anti-B7 treatment, the numbers of VSAg-reactive T
cells were generally lower in the periphery than in the thy-
mus, although the effect of anti-B7 was more pronounced
among the peripheral T cells. Both observations can be due
to the fact that the deletion of superantigen-specific T cells
is a late event in thymic T cell development (24). Perhaps
T cells migrate to the periphery only when the deletion is
complete. Alternatively, one can speculate that the clonal
deletion of these T cells continues in the periphery. Re-
gardless of which interpretation is correct, our data demon-
strated that the deletion of VSAg-specific T cells in the thy-
mus can be prevented by anti-B7, and that the rescued cells
can survive and migrate to the periphery.
Pathogenicity of VSAg-specific T Cells Rescued by Perinatal
Anti-B7 Treatment. To directly evaluate the pathogenicity
of VSAg-reactive T cells rescued by anti-B7 mAbs, we pu-
rified V 3, V 5, V 11, or V 12  T cells from either the
spleens or thymi of mice that had received anti–B7-1 and
anti–B7-2 mAbs during the perinatal period, and adop-
tively transferred them (106 spleen T cells per mouse, or
Figure 2. Anti-B7 mAb treatment
increases the amount of mature
CD4 CD8 V 8 T cells in the
spleen. Top panels show the expres-
sion of the CD8 coreceptor, whereas
the lower panels show the expres-
sion of CD44 activation markers.
Among the P1A and P1CTL double
transgenic mice, anti–B7- and the
control Ig-treated groups have a
similar number of V 8  transgenic
T cells. However, the number of
V 8 CD8  mature T cells is in-
creased by 2.5-fold in the anti–B7-
treated group. Data shown are the
contour plots of gated V 8  T cells
and are representative of three inde-
pendent experiments.963 Gao et al.
3    106 thymocytes enriched for CD4  V  3-, V 5-,
V 11-, or V 12-expressing cells) into lethally irradiated
syngeneic mice (VSAg ) with syngeneic bone marrow
cells (107 per mouse; group A, n   7). The irradiated recip-
ients were used to ensure the grafting of small numbers of
T cells and the presence of B cells, the primary VSAg-
expressing cells (26). After depleting the T cells expressing
V 3, V 5, V 11, and V 12, the remaining V 3, V 5,
V 11, V 12  thymocytes (3   107 per mouse) were also
cotransferred (group B, n   3) with bone marrow cells for
control for flow cytometry. A third group of mice (group
C, n   5) that had received bone marrow cells, but not T
cells, was also used as a control for pathogenicity of the
adoptively transferred T cells. As shown in Fig. 4 a, the
mice that received a mixture of V 3, V 5, V 11, or
V 12  T cells from anti–B7-treated thymi had a high pro-
portion of T cells expressing these V . The most remark-
able subsets were the V 11  and V 12  T cells, which
consisted of 38.5% and 12.1% of the CD4 T cells, respec-
tively. These T cells were not newly produced from bone
marrow, as the control group that received the V 3, V 5,
V 11, V 12  T cells and bone marrow had few T cells
expressing any of these V  chains (Fig. 4 a, left). Thus, the
VSAg-specific T cells were not deleted in the mice that ex-
pressed the superantigen. Moreover, considering the fact
that relatively few T cells (106 per mouse) were injected,
and that most of the T cells injected tended to disappear
upon adoptive transfer, these T cells must have expanded
substantially. Consistent with this, an overwhelming ma-
jority of the VSAg-specific T cells exhibited a cell surface
phenotype of CD44hi and CD62Llo, which revealed their
antigenic experience. The substantial expansion of T cells
in the recipient indicated that these cells had not been an-
ergized in anti–B7-treated mice.
On days 7 and 8 of adoptive transfer of V 3, V 5,
V 11, V 12  T cells from anti–B7-treated mice, two of
the seven recipients developed diarrhea with gastrointesti-
nal hemorrhage. One died of diarrhea 2 d later, and the
others survived. At 3–4 wk, the recipients were killed
based on their health status and were analyzed for both the
presence of the VSAg-specific T cells and for pathological
signs of autoimmune destruction. Histological analysis re-
vealed extensive lymphocyte infiltration in multiple organs
(Fig. 5 a). All of the six mice that received V 3, V 5,
V 11, V 12  T cells and survived had severe inflamma-
tion in the lung and intestine. The majority of them (four
out of six) also had lymphocyte inflammation in the liver.
With the exception of one mouse that had mild inflamma-
Figure 3. Perinatal B7-blockade rescues VSAg-specific T cells in the thymus and in the periphery. BALB/c mice were treated with either anti-B7 or
control IgG during the perinatal period. 4 wk after birth the thymi, spleens, and lymph nodes were harvested and stained with a cocktail of anti-CD4,
anti-CD8, and anti-V  mAbs. (a) FACS® profiles depict the V  subset distribution of gated CD4 CD8  or CD4 CD8  thymocytes. The numbers
given in each panel are the percentage of cells expressing the given V s. Data from one representative thymus in each group is presented. (b) Percentages
of V  expressing CD4 CD8 , CD4 CD8  thymocytes, spleen cells, and lymph node cells. Data shown are   SEM from an experiment involving 2 or
3 mice per group that was repeated three times.964 A Critical Role for Costimulation in Clonal Deletion of Autopathogenic T Cells
tion in the lung, no histological lesion was observed in the
control mice that had only received bone marrow. To con-
firm that the VSAg-specific T cells were involved in the in-
flammation, we also analyzed V 3  and V 11  T cells in
the pathological lesions. As shown in Fig. 5 b, massive
V 3  and V 11  T cells were found in the inflammatory
sites in the intestines, although the number of V 3  cells
was less than that of V 11  cells. Thus, the VSAg-specific
T cells rescued by perinatal treatment with anti-B7 mAbs
are pathogenic to syngeneic hosts. These data directly dem-
onstrated the strong pathogenicity of VSAg-reactive T cells
that escape central deletion as a result of B7 blockade, al-
though it is possible that the VSAg are the target antigens
recognized by the V 3, V 5, V 11, V 12  T cells.
Interestingly, V 3, V 5, V 11, V 12  thymocytes
were also pathogenic in the same setting. Two of the three
recipients developed diarrhea on days 7 and 8, and one of
the two also developed gastrointestinal hemorrhage and
died on day 9. Two mice that survived were examined by
necropsy. Both mice had severe inflammation in the lung,
intestine (Fig. 5 c), and liver (unpublished data). These re-
sults suggest that the VSAg-specific T cells are only a subset
of the autoreactive T cells rescued by perinatal anti-B7
treatment.
Perinatal Blockade of B7-1 and B7-2 Induces Autoreactive T
Cells That Are Lethal in Young Immune-deficient Recipients.
To substantiate the role for B7 in promoting the clonal de-
letion of autopathogenic T cells, aside from those that are
reactive to VSAg, we treated the VSAg-negative C57BL/6
mice from day 16 of embryonic development in the
mother to day 10 after birth with either control normal (rat
and hamster) IgG or a mixture of anti–B7-1 and anti–B7-2
mAbs. This treatment did not substantially alter the repre-
sentation of the major subset of thymocytes (unpublished
data). At 2–3-wk-old, the percentage of CD4 CD25  T
cells in the thymus of mice treated with anti-B7 mAbs was
not significantly different from that of mice treated with
control IgG (unpublished data). Although anti-B7 treat-
ment increased the total number of the thymocytes by 30–
100%, the number of dendritic cells in the spleen and
thymus was not reduced by the anti-B7 treatment (unpub-
lished data). When the mice reached 3-wk-old, and the
circulating anti-B7 mAb remained high (unpublished data),
male mouse thymocytes were enriched for CD4 T cells and
injected intraperitoneally into RAG-1 /  mice that lacked
T and B lymphocytes. As shown in Fig. 6 a, top, thy-
mocytes from anti–B7-1– and anti–B7-2–treated mice rap-
idly killed the syngeneic recipients. The mice that had re-
ceived a high dose of thymocytes from anti–B7-treated
mice all died within 1 wk of adoptive transfer, whereas
those that had received the same amount of thymocytes
from the control IgG-treated group grew into adult age
with no apparent growth retardation. A 10-fold reduction
in the number of thymocytes transferred decreased mortal-
ity and delayed disease onset. Necropsies revealed that the
recipients of thymocytes or T cells from anti–B7-1– and
anti–B7-2–treated mice died of severe mononuclear cell
inflammation in multiple organs, such as the lung, pancreas,
Figure 4. Presence and pathogenicity of VSAg-specific T cells res-
cued by perinatal treatment with anti-B7 mAbs. Lethally irradiated
BALB/c mice (900 rad) were adoptively transferred with 107 per mouse
of syngeneic bone marrow cells and 3   106 per mouse of thymocytes,
enriched for their expressing either V 3, V 5, V 11, or V 12. As con-
trol, 3   107 thymocytes depleted of the V 3-, V 5-, V 11-, and
V 12-expressing cells were also adoptively transferred together with
syngeneic bone marrow cells. 3 wk after adoptive transfer, the recipient
mice were killed and the spleen cells were analyzed. (a) Large numbers
of VSAg-specific T cells were found in syngeneic VSAg-expressing mice
that received bone marrow plus V 3, V 5, V 11, or V 12  cells
(right), but not those that received bone marrow plus V 3, V 5, V 11,
and V 12  cells (left). Data shown were gated CD4  cells from spleen
cells and are representative of the CD4 T cells from all five mice ana-
lyzed. The numbers in the panels are the percentage of cells expressing
given V  among CD4  T cells. (b) The majority of the VSAg-reactive
T cells expressed markers of antigen-experienced T cells. Spleen cells in
the chimera mice were stained with FITC-conjugated mAbs specific
against V 3, V 5, V 11, or V 12. Cychrome–anti-CD44 and PE–
anti-CD62L mAbs were added. Data shown in the left panels are histo-
grams for distribution of V 3-, V 5-, V 11-, or V 12-expressing cells.
The data shown in the right are dot plots depicting the expression of
CD44 and CD62L.965 Gao et al.
liver, heart, and intestine (Fig. 6 b and unpublished data).
For example, in the RAG-1 /  recipients of thymocytes
from anti–B7-treated mice, infiltration of lymphocytes and
macrophages, but not neutrophils, caused severe destruc-
tion of the majority of lung parenchyma. Multiple foci of
mononuclear cell infiltration and interstitial edema in the
myocardium of the heart were also observed (Fig. 6 b, up-
per left). In contrast, no infiltration of lymphocytes was ob-
served in any of the organs of the recipients of thymocytes
from the control IgG-treated mice, even when analyzed 2
mo after adoptive transfer (Fig. 6 b, bottom). These results
demonstrate that the perinatal blockade of B7-1 and B7-2
leads to an accumulation of lethal autoreactive T cells in
the thymus.
To test if the autoreactive thymocytes can exit to the pe-
riphery, spleen T cells isolated from the same anti–B7-
treated mice were adoptively transferred into syngeneic
nu /nu  mice. The spleen T cells killed all recipient mice
within 2 wk. Massive inflammation of the lung, liver, in-
testine, muscle, and pancreas was observed in necropsies
(Fig. 6 b and unpublished data). For example, all of the
mice examined had pancreatitis characterized by interstitial
lymphoid infiltration, fibroblast proliferation, the formation
of lymphoid aggregates, and the destruction of some pan-
creatic lobules. Some mice had mononuclear cell infiltra-
tion in the muscles and the nerves. In contrast, with the ex-
ception of one accidental death, the mice that had received
spleen T cells from the control IgG-treated mice were
healthy, and grew well into adulthood (Fig. 6 a, bottom).
Mice that had received spleen T cells from control IgG-
treated mice were histologically normal in all organs exam-
ined. Additional experiments indicated that a total of 100  
106 thymocytes were as efficient as 20   106 spleen T cells
in inducing lethal autoimmune disease in young nu /nu 
mice (unpublished data).
Multiple Organ Inflammation and T Cell Activation in Adult
Recipients of T Cells from Anti–B7-treated Mice. When T
cells from anti–B7-treated spleens were transferred into the
adult RAG-1 /  mice, the inflammations were more
chronic and the recipients lived for more than 3 mo after
adoptive transfer. During this period, we observed signifi-
cant growth retardation among the recipients of spleen T
cells from anti–B7-treated mice (unpublished data). 3 mo
after adoptive transfer, some recipients of the anti–B7-
treated T cells became moribund, whereas those that re-
ceived T cells from the control IgG-treated mice remained
healthy. Histological analysis revealed that the recipients of
spleen T cells from anti–B7-treated mice developed severe
chronic inflammation in multiple organs, including the
lung, pancreas, intestine (Fig. 7 a), and liver (unpublished
Figure 5. T cells from mice with perinatal B7 blockade caused acute
GVHD in syngeneic recipients. Pathogenicity of VSAg-reactive (a and b)
and -nonreactive (c) T cells. (a) H&E staining of intestines (top) and lungs
(bottom) from mice 4 wk after adoptive transfer of either 107 per mouse
of bone marrow cells alone (left) or bone marrow plus 3   106 per mouse
of VSAg-reactive T cells isolated from the thymi of mice perinatally
treated with anti–B7-1 and anti–B7-2 mAbs (right). (b) Infiltration of
V 3  and V 11  T cells in the intestine. Intestine sections, of mice that
had received both bone marrow cells and VSAg-reactive T cells as de-
scribed in panel a were stained with anti–V 3 (hamster) or anti–V 11
(rat) mAbs. Two sections of 40  and 200  are shown for each staining.
Isotype controls (40 ) for the two mAbs are shown in the top panels. (c)
Mice that received thymocytes depleted of V 3, V 5, V 11, and V 12 
T cells developed severe inflammation of the lung (left), intestines (right),
and liver (unpublished data). The details are as described in panel a, except
that after depleting the VSAg-reactive T cells, the remaining CD4-
enriched thymocytes (3   107 per mouse) and 107 syngeneic bone mar-
row cells were transferred into lethally irradiated syngeneic VSAg  recipi-
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data). Immunohistochemical analysis revealed that the lung
infiltrates consisted mainly of CD4 T cells and macro-
phages, although significant numbers of CD8 T cells were
observed (Fig. 7 b). In contrast, no significant inflammation
was observed in the recipients of T cells from control IgG-
treated mice. The recipients of anti–B7-treated T cells also
had significantly higher numbers of T cells in the spleens,
lymph nodes, and thymi, and most of these T cells exhib-
ited markers of antigen-experienced cells (Fig. 7 c). Anti-
gen-experienced T cells produce cytokine more rapidly
than naive T cells when triggered by either antigen or ago-
nists of the T cell receptors (27). To determine the extent
of T cell activation, spleen T cells were analyzed for the
production of a panel of cytokines such as IL-2, IL-4, IL-
10, and IFN-  after stimulation with PMA and ionomycin.
As shown in Fig. 7 d, in the mice that had received anti–
B7-treated T cells, the number of IFN- –producing cells
was significantly elevated. This elevation was observed in
both CD4 and CD8 compartments. Surprisingly, a large
number of CD4 CD8  spleen cells expressed IFN- . The
increase of this population corresponded to a significant in-
crease of the TCR  CD4 CD8  T cells in the spleen.
The accumulation of antigen-experienced CD4 CD8  T
cells recapitulates an important feature of autoimmune
mice (28). Interestingly, the number of cells expressing IL-
2, IL-4, and IL-10 were low and comparable between the
two groups of mice (unpublished data). A selective increase
of IFN- –expressing cells indicated that anti–B7-treated
spleen cells were polarized toward the Th1 subset in the
RAG-1 /  recipients.
To test if the mice that received anti-B7 mAbs during
the perinatal period developed autoimmune diseases, the
mice were left untreated after the perinatal period and
killed for histological examination 1, 2, and 5 mo after an-
tibody treatment. In comparison to control IgG-treated
mice, the anti–B7-treated mice had increases in both the
number and severity of pathological lesions in multiple or-
gans as early as 1 mo after the antibody treatments (unpub-
lished data). 2 mo after treatment, the inflammation exacer-
bated substantially. The pathological and immunological
effects of perinatal treatment with anti-B7 mAbs are pre-
sented in Fig. 8. As shown in Fig. 8 a, both male and fe-
male mice that received anti-B7 during the perinatal period
had severe mononuclear cell infiltration in the lung. The
majority of anti–B7-treated female mice had inflammation
in the kidney, whereas the control female mice had little
kidney inflammation. No inflammation in the kidney was
observed in male mice regardless of the treatment during
the perinatal period. Corresponding to increased patholog-
ical lesions, lymphoproliferation was observed in anti–B7-
treated mice. Thus, in comparison with control IgG-
treated mice, the T cell numbers in the lymph nodes
increased by three- to fivefold (unpublished data). The
number of activated T cells, as indicated by CD69hi and
Figure 6. Lethal autoimmune T cells induced by a perinatal blockade of costimulatory molecules B7-1 and B7-2. C57BL/6j mice were treated with a
mixture of anti–B7-1 and anti–B7-2, or rat and hamster IgG as control, from day 16 of pregnancy to day 10 after birth. 3 wk after birth, CD4-enriched
thymocytes were prepared from anti–B7-treated and control IgG-treated male mice, respectively, and injected in high (hi, 2   108 per mouse) or low
(lo, 2   107 per mouse) doses into 14-d-old syngeneic RAG-1 /  mice. Purified spleen T cells (2   107 per mouse) were isolated from both groups of
mice and were adoptively transferred intraperitoneally into 2-wk-old, syngeneic nu /nu  mice. The recipients were monitored every day, and dead or
moribund mice were subject to necropsies. (a) Rapid onset of fatal attack by either CD4-enriched thymocytes (top, n   5) or spleen T cells (bottom, n   5
for anti–B7-treated group; n   4 for control IgG-treated group). (b) Histology of lung and heart sections from a RAG-1 /  recipient (upper left), and a
pancreas, a muscle (M) and nerve (N) sections of a nu /nu  recipient (upper right). The organs from recipients of T cells from control Ig-treated mice
were harvested 2 mo after adoptive transfer (bottom). The data shown are representative of two independent experiments.967 Gao et al.
CD62Llo phenotypes, also increased significantly (Fig. 8 b).
The percentage of IFN- –producing cells increased by
threefold in anti–B7-treated mice (Fig. 8 b). By month 5,
although the numbers of IFN- –producing cells remained
higher, the pathological lesions were largely resolved in
anti–B7-treated mice (unpublished data), perhaps due to
immune regulation by the endogenous T cells.
Discussion
The perinatal period is the most important for the forma-
tion of T cell repertoire. However, the contribution of in-
teractions other than that of TCR–MHC antigen has not
been systematically evaluated for this period. Here, we have
addressed the biological significance of B7-1– and B7-2–
mediated clonal deletion of autoreactive T cells during the
perinatal period. Our results reveal that these costimulatory
molecules make a substantial contribution for T cell clonal
deletion and that the blockade of these interactions results in
an accumulation of highly pathogenic autoreactive T cells.
Using a transgenic model, we have shown that perinatal
treatment with anti-B7 mAbs prevents the clonal deletion
of antigen-specific T cells. Moreover, even in conventional
mice with a polyclonal TCR repertoire, anti-B7 prevented
the deletion of T cells specific for VSAg. The results dem-
onstrate that costimulatory molecules B7-1 and B7-2 play
an important role in T cell clonal deletion. The effect of
anti-B7 blockade, in terms of both the spectrums (all four
V s among CD4 T cells, and three of the four V s among
CD8 T cells) and the quantity (three- to sixfold increase of
VSAg-reactive T cells in the periphery in most cases) of the
effect, argues for the critical role of B7-mediated costimu-
lation in the clonal deletion of a significant portion of, al-
though certainly not all, self-reactive T cells, especially in
cases in which the antigens are limiting or the affinity of
antigen–TCR interaction is low. Our results significantly
extend the previous studies on possible contribution of
CD28 (15–18, 29–32) and CTLA4 (33) to T cell clonal de-
letion. As we have reported, the greater contribution of
B7-1 and B7-2 than of CD28, as reported by Li and Page
Figure 7. Perinatal blockades of B7-1– and B7-2–induced T cells that cause chronic autoimmune inflammation in adult RAG-1 /  recipients. Spleen
T cells were isolated from 3-wk-old female C57BL/6j mice that had received either anti-B7 mAbs or control IgG and injected intraperitoneally (2   107
per mouse) into 6-wk-old, syngeneic female RAG-1 /  mice (n   5 per group). The recipient mice were killed 3 mo after adoptive transfer. (a) H&E
staining of lung, liver, and colon sections. In the anti–B7-treated group, multinucleated giant cell granulomas, characteristic of chronic inflammation, were
present in the lung. Pancreatic acini were infiltrated by mononuclear cells, and neolymphoid follicles were observed in some mice. The villi of the small
intestine were densely infiltrated by lymphocytes (unpublished data), and in some areas inflammatory cells were present in the submucosa and muscularis
externa of the colon. The sections presented are from a representative mouse from each group. All mice that received T cells from anti–B7-treated mice
developed severe inflammation in the lung, liver, pancreas, and intestine, whereas the recipients of control IgG-treated T cells were histologically normal,
with occasional foci or inflammation in the lung. (b) Immunohistochemical analysis of lung sections using anti-CD4, anti-CD8 and anti–Mac-1 antibodies.
The pictures were taken from the same anatomic location of three consecutive sections. (c) Numbers and phenotypes of T cells in the spleens and lymph
nodes of RAG-1 /  mice that were adoptively transferred with splenic T cells from anti–B7-treated mice. Splenocytes and lymph node cells were isolated,
counted, stained with FITC-conjugated anti-TCR  , PE-conjugated anti-CD4, and Cychrome–conjugated anti-CD8 (left and middle), or FITC-conju-
gated anti-TCR  , PE-conjugated anti-CD62L, and Cychrome–conjugated anti-CD8, and were analyzed with flow cytometry. The number of
CD4 CD8  T cells were obtained by subtracting the CD4 CD8  and CD8 CD4  T cells from the TCR  T cells. (d) Intracellular cytokine expression
in the T cells. Data shown are expressions of IFN-  from gated CD4, CD8, and CD4 CD8  lymphocytes. No alteration in the number of IL-2–, IL-4–,
and IL-10–producing cells was observed (unpublished data). Data shown were representative of two to three independent experiments.968 A Critical Role for Costimulation in Clonal Deletion of Autopathogenic T Cells
(18), raised the possibility that non-CD28 receptor for B7-1
and B7-2 may be involved in clonal deletion.
The contribution of B7 to the clonal deletion of VSAg-
reactive T cells prompted us to test whether these T cells are
pathogenic in a syngeneic host. We enriched the VSAg-
reactive T cells rescued by perinatal treatment of anti–B7-1
and anti–B7-2 blockade and transferred them into irradiated
hosts. Our analysis indicated that these VSAg-reactive T
cells expanded substantially, and induced severe inflamma-
tion in multiple organs. These results directly demonstrate
that the VSAg-reactive T cells that escape clonal deletion as
a result of B7 blockade are highly pathogenic.
However, the autopathogenic T cells are not limited to
VSAg-reactive cells, as anti-B7 also rescues autoreactive T
cells in C57BL/6j mice that are pathogenic in the synge-
neic VSAg  host (C57BL/6). In three distinct settings, we
have shown that perinatal treatment with both anti–B7-1
and anti–B7-2 mAbs induces pathogenic self-reactive T
cells in both the thymus and spleen. Upon adoptive trans-
fer, both thymocytes and spleen T cells killed the syngeneic
young recipients within 1 to 2 wk. They died of severe
multiple organ inflammation. Although the adult recipients
survived the acute autoimmune attack, severe chronic au-
toimmune diseases developed within 3 mo of adoptive
transfer. Thus, the adult recipients were less susceptible to
the autoreactive T cells. The extreme susceptibility of the
young (2–3-wk-old) recipients may explain, at least in part,
the lethal lymphoproliferative disease in young scurfy (34)
and CTLA4 /  mice (3, 4). The relative contribution of
the defective T cell development, as described here, and
the potential effect of B7 blockade on the regulatory T
cells, as others have postulated (5), to the exacerbated au-
toimmune disease in mice with targeted mutation of B7-2
(6), CD28 (5), and CTLA-4 (3–5), remains to be resolved.
This study described several models that can be used to an-
alyze this important question.
Perhaps the most direct setting in which to evaluate the
pathogenicity is the autoimmune phenotype of the mice
that received anti-B7 during the perinatal period. Although
we observed severe and spontaneous inflammations in mul-
tiple organs of these mice, the autoimmune diseases in the
adoptive transfer models were more severe than in mice
that were directly treated with anti-B7 mAbs during the
perinatal period. This difference can be explained, at least
in part, by the role of B7 molecules in the activation (35),
survival (36), and effector function (37, 38) of self-reactive
T cells. In the adoptive transfer model, the injected anti-B7
mAbs were washed away before T cell transfer. However,
Figure 8. Autoimmune inflammatory response in mice
that received anti-B7 mAbs during the perinatal period. 2
mo after the antibody treatment, the mice were killed and
the internal organs were fixed with 10% formalin and exam-
ined by H&E staining. (a) Scores of histological lesions in ei-
ther control ( ) or anti–B7-treated mice ( ). The scores of
lung and kidney lesions were presented. The data shown are
summarized from three independent experiments. (b) Phe-
notypic and functional characterization of the spleen T cells.
Spleen cells were analyzed for the cell surface expression of
CD69 and CD62L and intracellular expression of IFN- .
The subsets of T cells were marked by a combination of
FITC-conjugated anti-CD4 and Cychrome–conjugated
anti-CD8 mAbs. Data from gated CD4 T cells are presented,
although similar results were obtained among the gated CD8
T cells. No alteration in the number of IL-2–, IL-4–, and
IL-10–producing cells was observed. Data shown are repre-
sentative of three independent experiments.969 Gao et al.
in the mice that had received antibody treatment, the in-
jected anti–B7-2 mAbs were present at high levels for at
least 3 wk after the treatment, whereas anti–B7-1 mAbs
were detected for at least 10 wk after the injections (un-
published data). The residual anti-B7 mAbs can inhibit the
autoimmune response, as has been reported in many mod-
els (39). Moreover, autoreactive T cells may die as a result
of TCR engagement in the absence of costimulation (36).
Similarly, because the activation and/or effector function of
self-reactive T cells requires B7-1 and B7-2 on the antigen-
presenting cells in the periphery (40, 41), one would not
necessarily expect gross autoimmune disease in mice with
targeted mutations of both B7-1 and B7-2 (42, 43), al-
though NOD mice with a mutation of B7-2 do develop
spontaneous peripheral polyneuropathy (6). In addition,
homeostatic proliferation in the lymphopenic mice may
have exacerbated the autoimmune disease. However, be-
cause T cells from control IgG-treated mice were not
pathogenic in the same model, the homeostatic prolifera-
tion was insufficient to cause the strong autoimmunity, as
we have observed here.
Because autoreactive T cells accumulate in the thymus as
a result of anti-B7 blockade, our results would suggest a
B7-dependent central tolerance mechanism that is normally
responsible for the elimination of lethal autoreactive T
cells. A caveat of this interpretation is that the autoreactive
T cells in the thymus of anti–B7-treated mice may have
migrated from the periphery. To rule out this possibility,
we tested if the autoreactive T cells in the spleen can mi-
grate to the thymus. Our results demonstrated that when T
cells from the spleens of anti–B7-treated mice were labeled
with fluorescent dye and injected into the control Ig-
treated mice, they readily homed to the spleens and lymph
nodes, but not to the thymi (unpublished data). Therefore,
it is very unlikely that a sufficient number of autoreactive
spleen cells can migrate into the thymus at 3–4-wk-old.
Given the high efficiency of the thymocytes in inducing
inflammation in syngeneic mice, the most likely interpreta-
tion is that autoreactive T cells were rescued by anti-B7 in
the thymus.
Taken together, our results demonstrate that costimula-
tion by B7-1 and B7-2 plays a critical role in the intrathy-
mic deletion of a wide spectrum of autoreactive T cells,
and the cells rescued by B7 blockade are extremely respon-
sive to antigen in vivo. More strikingly, the blockade of B7
leads to an accumulation of highly pathogenic autoreactive
T cells. The strong effect of the B7 blockade on T cell
clonal deletion suggests that the accumulation of pathologic
autoreactive T cells results from a blockade of T cell clonal
deletion. The fact that the VSAg-specific T cells rescued by
anti-B7 are highly pathogenic in syngeneic mice provides
strong support for this hypothesis. Although the frequency
of autoreactive T cells that escape clonal deletion as a result
of perinatal B7 blockade cannot be accurately determined
at this stage, we believe it is likely to be high based on the
percentage of VSAg-reactive cells, and on the strong
pathogenicity of the thymocytes and spleen T cells from
anti–B7-treated mice. The significant increase of patho-
genic autoreactive T cells and the proposed role for costim-
ulatory molecules in the activation of regulatory T cells (5)
may both contribute to the paradoxical increase of autoim-
munity in mice deficient for B7-2 (6), CD28 (5), or
CTLA-4 (3, 4).
T cell self-tolerance is induced and maintained by both
central and peripheral tolerances. Abundant evidence has
established the importance of both processes in eliminating
self-reactive T cells (21, 22, 44–46). Although genetic evi-
dence has established the importance of peripheral toler-
ance in preventing autoimmune attack (47, 48), we are not
aware of direct proof for the thesis that defective central
tolerance can cause autoimmune disease. Recent studies
have indicated that a population(s) of cells in the thymus,
termed peripheral antigen-expressing cells, can express an-
tigens previously assumed to be in specific peripheral tissues
(20, 49). Expression of these antigens in the thymus corre-
lates to the induction of immune tolerance (50, 51), and
susceptibility to autoimmune diseases (50, 52). Our results
demonstrate that the perinatal blockade of B7-1 and B7-2
reduced the efficacy of clonal deletion and led to an accu-
mulation of lethal autoreactive T cells in the thymus and
spleen. The severity and the high penetration of the disease
argue for a strong selection pressure during evolution for an
efficient mechanism for central T cell tolerance. It is likely
that central tolerance removes the bulk of autoreactive T
cells, in which B7 plays a critical role, whereas peripheral
mechanisms act as a fail-safe to prevent chronic autoim-
mune disease, such as those observed in patients or animals
with spontaneous mutations that inactivate peripheral tol-
erance (47, 48).
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